Peter Alff

Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ.

Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ.

Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA.

Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA.

Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ.